An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency

Interventions

BIOLOGICAL: IgPro

Sponsor

CSL Behring